bendamustine hydrochloride

FDA Drug Profile — bendamustine hydrochloride, Bendeka, BENDAMUSTINE HYDROCHLORIDE, BELRAPZO

Drug Details

Generic Name
bendamustine hydrochloride
Brand Names
bendamustine hydrochloride, Bendeka, BENDAMUSTINE HYDROCHLORIDE, BELRAPZO
Application Number
ANDA205574
Sponsor
Accord Healthcare, Inc.
NDC Codes
7
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, POWDER, INJECTION, SOLUTION, INJECTION
Routes
INTRAVENOUS
Active Ingredients
BENDAMUSTINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS & USAGE VIVIMUSTA is an alkylating drug indicated for treatment of patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) VIVIMUSTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) VIVIMUSTA is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.